Ultragenyx Pharmaceutical (RARE) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Ultragenyx Pharmaceutical Revenue Highlights

Latest Revenue (Y)

$434.25M

Latest Revenue (Q)

$147.03M

Main Segment (Y)

Royalty

Main Geography (Y)

North America

Ultragenyx Pharmaceutical Revenue by Period

Ultragenyx Pharmaceutical Revenue by Year

Date	Revenue	Change
2023-12-31	$434.25M	19.52%
2022-12-31	$363.33M	3.39%
2021-12-31	$351.41M	29.66%
2020-12-31	$271.03M	161.32%
2019-12-31	$103.71M	101.41%
2018-12-31	$51.49M	1871.48%
2017-12-31	$2.61M	1863.91%
2016-12-31	$133.00K	100.00%
2015-12-31	-	100.00%
2014-12-31	-	100.00%
2013-12-31	-	100.00%
2012-12-31	-	100.00%
2011-12-31	-	-

Ultragenyx Pharmaceutical generated $434.25M in revenue during NA 2023, up 19.52% compared to the previous quarter, and up 843.28% compared to the same period a year ago.

Ultragenyx Pharmaceutical Revenue by Quarter

Date	Revenue	Change
2024-06-30	$147.03M	35.09%
2024-03-31	$108.83M	-14.57%
2023-12-31	$127.39M	29.92%
2023-09-30	$98.05M	-9.47%
2023-06-30	$108.31M	7.77%
2023-03-31	$100.50M	-2.76%
2022-12-31	$103.35M	13.94%
2022-09-30	$90.70M	1.52%
2022-06-30	$89.34M	11.77%
2022-03-31	$79.94M	-4.14%
2021-12-31	$83.39M	2.13%
2021-09-30	$81.65M	-6.13%
2021-06-30	$86.97M	-12.50%
2021-03-31	$99.39M	8.58%
2020-12-31	$91.54M	12.36%
2020-09-30	$81.47M	32.02%
2020-06-30	$61.71M	69.96%
2020-03-31	$36.31M	2.01%
2019-12-31	$35.59M	37.96%
2019-09-30	$25.80M	6.84%
2019-06-30	$24.15M	32.89%
2019-03-31	$18.17M	11.75%
2018-12-31	$16.26M	38.24%
2018-09-30	$11.76M	-8.06%
2018-06-30	$12.79M	19.83%
2018-03-31	$10.68M	342.29%
2017-12-31	$2.41M	1119.19%
2017-09-30	$198.00K	100.00%
2017-06-30	-	100.00%
2017-03-31	-	-100.00%
2016-12-31	$5.00K	-95.50%
2016-09-30	$111.00K	552.94%
2016-06-30	$17.00K	100.00%
2016-03-31	-	100.00%
2015-12-31	-	100.00%
2015-09-30	-	100.00%
2015-06-30	-	100.00%
2015-03-31	-	100.00%
2014-12-31	-	100.00%
2014-09-30	-	100.00%
2014-06-30	-	100.00%
2014-03-31	-	100.00%
2013-12-31	-	100.00%
2013-09-30	-	100.00%
2013-06-30	-	100.00%
2013-03-31	-	100.00%
2012-12-31	-	-

Ultragenyx Pharmaceutical generated $147.03M in revenue during Q2 2024, up 35.09% compared to the previous quarter, and up 146.30% compared to the same period a year ago.

Ultragenyx Pharmaceutical Revenue Breakdown

Ultragenyx Pharmaceutical Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Royalty	$182.65M	-	-	-	-
Product	$180.41M	-	-	-	-
Collaboration And License	$71.18M	$7.69M	$85.00M	$89.22M	$504.00K

Ultragenyx Pharmaceutical's latest annual revenue breakdown by segment (product or service), as of Dec 23: Royalty (42.06%), Product (41.55%), and Collaboration And License (16.39%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Dec 19	Sep 19	Jun 19
Royalty	$62.24M	$73.22M	$46.34M	$126.95M	$55.70M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product	$77.25M	$73.81M	$62.49M	$138.06M	$42.35M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration And License	-	-	-	$69.70M	$1.48M	$1.48M	$1.48M	$1.48M	$3.25M	$8.23M	$12.06M	$21.96M	$42.75M	$37.50M	$32.87M	$18.86M	$51.00K	$101.00K	$68.00K	-

Ultragenyx Pharmaceutical's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (55.38%), and Royalty (44.62%).

Ultragenyx Pharmaceutical Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
North America	$307.15M	$281.09M	$301.11M	$237.67M	-
Europe	$47.53M	$36.37M	$26.66M	$21.32M	$12.09M
JAPAN	$2.22M	$1.16M	-	-	-
Latin America	$77.34M	$44.71M	-	-	-
All Other	-	-	$23.64M	$12.05M	$5.19M
UNITED STATES	-	-	-	-	$86.44M

Ultragenyx Pharmaceutical's latest annual revenue breakdown by geography, as of Dec 23: North America (70.73%), Latin America (17.81%), Europe (10.95%), and JAPAN (0.51%).

Quarterly Revenue by Country

Country	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
North America	$76.91M	$88.89M	$57.68M	$92.92M	$67.81M	$79.29M	$67.13M	$70.89M	$66.91M	$75.57M	$87.74M	$82.73M	$72.65M	-	-	-	-	-	-	-
Asia Pacific	$2.31M	$3.05M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Latin America	$38.05M	$38.93M	$35.18M	$18.25M	$17.23M	$19.07M	$22.80M	$8.26M	$14.12M	$12.54M	$9.79M	$7.49M	$4.71M	-	-	-	-	-	-	-
EMEA	$22.22M	$16.16M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
JAPAN	-	-	-	$1.05M	-	-	$1.18M	-	$1.16M	-	-	-	-	-	-	-	-	-	-	-
Europe	-	-	$15.97M	$15.18M	$13.01M	$9.95M	$9.39M	$10.26M	$8.41M	$9.48M	$8.23M	$7.08M	$7.24M	$6.70M	$5.64M	$5.61M	$5.00M	$6.55M	$4.16M	$3.56M
U.S. and Canada	-	-	-	-	-	-	-	-	$67.01M	$67.33M	$61.92M	-	-	-	-	-	-	-	-	-
All Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$6.02M	$3.20M	$3.82M	$3.23M	$1.79M	$1.91M
UNITED STATES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$51.93M	$30.36M	$30.12M

Ultragenyx Pharmaceutical's latest quarterly revenue breakdown by geography, as of Sep 24: North America (55.14%), Latin America (27.28%), EMEA (15.93%), and Asia Pacific (1.66%).

Ultragenyx Pharmaceutical Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
INCY	Incyte	$3.70B	$962.99M
UTHR	United Therapeutics	$2.33B	$748.90M
ALNY	Alnylam Pharmaceuticals	$1.83B	$420.15M
RARE	Ultragenyx Pharmaceutical	$434.25M	$147.03M
AMLX	Amylyx Pharmaceuticals	$380.79M	$416.00K
APLS	Apellis Pharmaceuticals	$366.28M	$176.57M
ARVN	Arvinas	$78.50M	$102.40M
RVMD	Revolution Medicines	$11.58M	-
CRNX	Crinetics Pharmaceuticals	$4.01M	-
XFOR	X4 Pharmaceuticals	-	$560.00K
PDSB	PDS Bio	-	-
DAWN	Day One Biopharmaceuticals	-	$20.07M
ABOS	Acumen Pharmaceuticals	-	-
INZY	Inozyme Pharma	-	-
KURA	Kura Oncology	-	-
TERN	Terns Pharmaceuticals	-	-

RARE Revenue FAQ

What is Ultragenyx Pharmaceutical’s yearly revenue?

Ultragenyx Pharmaceutical's yearly revenue for 2023 was $434.25M, representing an increase of 19.52% compared to 2022. The company's yearly revenue for 2022 was $363.33M, representing an increase of 3.39% compared to 2021. RARE's yearly revenue for 2021 was $351.41M, representing an increase of 29.66% compared to 2020.

What is Ultragenyx Pharmaceutical’s quarterly revenue?

Ultragenyx Pharmaceutical's quarterly revenue for Q2 2024 was $147.03M, a 35.09% increase from the previous quarter (Q1 2024), and a 35.75% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $108.83M, a -14.57% decrease from the previous quarter (Q4 2023), and a 8.30% increase year-over-year (Q1 2023). RARE's quarterly revenue for Q4 2023 was $127.39M, a 29.92% increase from the previous quarter (Q3 2023), and a 23.27% increase year-over-year (Q4 2022).

What is Ultragenyx Pharmaceutical’s revenue growth rate?

Ultragenyx Pharmaceutical's revenue growth rate for the last 3 years (2021-2023) was 23.57%, and for the last 5 years (2019-2023) was 318.70%.

What are Ultragenyx Pharmaceutical’s revenue streams?

Ultragenyx Pharmaceutical's revenue streams in c 23 are Royalty, Product, and Collaboration And License. Royalty generated $182.65M in revenue, accounting 42.06% of the company's total revenue Product generated $180.41M in revenue, accounting 41.55% of the company's total revenue Collaboration And License generated $71.18M in revenue, accounting 16.39% of the company's total revenue, up 826.15% year-over-year.

What is Ultragenyx Pharmaceutical’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Ultragenyx Pharmaceutical was Royalty. This segment made a revenue of $182.65M, representing 42.06% of the company's total revenue.